NCT06924970Phase 2Active not recruiting

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Study sponsor: Agios Pharmaceuticals, Inc. · AGIO

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-05-12Actual

Enrollment · participants59Actual

Source updated2026-09-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-20 · 2 fields changed

Completion date type

Recorded edit

− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit

− Previous value

2026-05

+ Updated value

2026-05-12

Check registry source

Posted 2026-04-23 · 3 fields changed

Participant count type

Recorded edit

− Previous value

Estimated

+ Updated value

Actual

Enrollment · participant count

Recorded edit

− Previous value

count: 56; type: ESTIMATED

+ Updated value

count: 59; type: ACTUAL

Recruitment status

Recorded edit

− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source